A case of mistaken identity --- Biomarkers for high risk premalignant breast lesions

D. Joseph Jerry, UMass Amherst and PVLSI
Karl Simin, UMass Medical
May 8th, 2013
Estimated costs: $20,000 to $100,000/patient.

Campbell JD, Ramsey SD. Pharmacoeconomics. 2009;27(3):199-209. PMID: 19354340
Atypical hyperplasias

Progression to invasive cancer

50,000 new cases annually

Expect 10,000 new cases annually

Up to $1B to treat
Developing biomarkers of high risk premalignant breast lesions

Subtypes of Atypical Hyperplasias

Subtypes of lesions with malignant potential

[Diagrams and images of breast tissues and biomarkers]
Bioanalyzer electropherograms

Intact RNA

FFPE RNA
Patient Registry
Survey data
Clinical data
Archived tissues

Data Manager
• Collate data
• Provides summary data
• Extract data from clinical records
• Coded data for IRB-approved projects

IRB-approved projects

Project 1
Project 2
Project 3
Project 4

Data/Tissue With Study ID

IRB-approved Registry
Patient consent
Assign study ID

Patient Population:
Diagnosis of Breast Cancer or Benign Breast Disease
Atypical hyperplasia (UMMS 1999-2003)

2833 breast core biopsies
120 with primary diagnosis of ADH

Upstaging upon re-excision
Summary

• Value of diagnostic test
  – Large interobserver variability in diagnosing premalignant lesions (Jain et al., 2011. PMID 21532546)
  – Identify subgroups to benefit from preventive therapies.
  – Identify molecular pathways to provide appropriate preventive treatments

• Technical challenges
  – Minute amounts of tissue
  – Fragmentation of RNA in FFPE tissues
  – Amplification and labeling for robust detection
University of Massachusetts - Amherst

D. Joseph Jerry, Ph.D.
Ellen Dickinson
Amy Roberts
Jeff Kane
Mary Hagen

Karen Dunphy
Haoheng Yan
Erick Roman
Nick Griner

UMass Medical Center
Karl Simin, Ph.D.
Ashraf Khan, M.D.

PVLSI

Sallie Smith Schneider, Ph.D.
Kelly Gauger

Baystate Medical Center
Grace Makari-Judson, M.D.
Giovanna Crisi, M.D.

Funding from
NIH, NIEHS, Avon Foundation
Rays of Hope Foundation,
Life Science Moment Fund